A Study Evaluating Ultratrace Iobenguane I 131 (MIBG) in Patients With Malignant Pheochromocytoma/Paraganglioma

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2015 by Molecular Insight Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Molecular Insight Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
First received: April 1, 2009
Last updated: October 5, 2015
Last verified: October 2015

This clinical trial is designed to evaluate the effectiveness and collect additional safety information on Ultratrace® Iobenguane I 131 for the treatment of relapsed/refractory (to other treatment) malignant pheochromocytoma and paraganglioma.

The purpose of this trial is to test the use of Ultratrace® iobenguane I 131 as a treatment for pheochromocytoma and paraganglioma type cancer. This Phase II study will help determine primarily if using the drug reduces the amount of blood pressure medication being taken as a result of the cancer and secondarily to determine such things as the effectiveness of the study drug in treating the cancer, additional safety measures, and to assess if the drug helps the quality of life and use of pain medication. All subjects will receive an imaging dose with scans followed by two therapy doses that are given 3 months apart.

Condition Intervention Phase
Radiation: Ultratrace® Iobenguane I131
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Resource links provided by NLM:

Further study details as provided by Molecular Insight Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Proportion of study subjects with a reduction (including discontinuation) of all antihypertensive medication by at least 50% for at least six months or two cycles of Ultratrace Iobenguane I 131. [ Time Frame: 12 Months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Proportion of subjects with overall tumor response of Complete Response or Partial Response by RECIST criteria [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
  • Safety assessed by changes in lab values, physical exams or vital signs, and the occurrence of treatment emergent adverse events [ Time Frame: 12 Months ] [ Designated as safety issue: Yes ]
  • Changes from baseline in overall quality of life [ Time Frame: 12 Months ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: 5 Years ] [ Designated as safety issue: No ]

Estimated Enrollment: 75
Study Start Date: June 2009
Estimated Study Completion Date: June 2021
Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ultratrace® Iobenguane I 131 Treatment Radiation: Ultratrace® Iobenguane I131
Each subject will be administered 3 mCi to 6 mCi Ultratrace® Iobenguane I 131, referred to as the Imaging Dose, to confirm that subject meets radiological entry criteria and to establish dosimetry. All subjects meeting entry criteria will then receive the investigational product referred to as the Therapeutic Dose (500 mCi or 8 mCi/kg if the subject weighs 62.5 kg or less) of Ultratrace Iobenguane I 131, followed by imaging at 7 days post infusion or upon discharge from isolation. The Therapeutic Doses will be adjusted equally if warranted by results of the dosimetry evaluation. At least 3 months later, subjects will receive the second Therapeutic Dose.
Other Name: Azedra™

Detailed Description:

Azedra™ Ultratrace® (Iobenguane I 131), commonly referred to as Ultratrace Iobenguane I 131, is a very high specific activity form of iobenguane I 131, produced using Molecular Insight's proprietary Ultratrace® platform. Based on the well characterized cellular active transport mechanism, the higher the specific activity of iobenguane I 131, the greater the cellular uptake of radioactivity and hence greater tumor uptake.

During this study the subjects will receive two (2) Therapy Doses that are given three (3) months apart. Prior to administration of the first Therapy Dose, subjects will be given an Imaging Dose of Ultratrace Iobenguane I 131 and will undergo iobenguane I 131 scans to evaluate tumor uptake and to measure normal organ distribution and allow for the calculation of radiation dose to normal organs.

Screening procedures for eligibility will need to be done before imaging or therapeutic doses of Iobenguane I 131 are administered.

Hospitalization is required for approximately one (1) week after each of the two (2) Therapeutic Doses. Frequent follow up is necessary for the first year and some of the follow up visits may be done by a visiting health care professional in the subjects' homes. Subjects will be followed in the treatment study for one (1) year and for an additional four (4) years in long-term follow up.


Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Be at least 12 years of age
  • Have a documented (medical record) diagnosis of either pheochromocytoma or paraganglioma
  • Be ineligible for curative surgery for pheochromocytoma
  • Have failed a prior therapy for pheochromocytoma/paraganglioma or are not candidates for chemotherapy or other curative therapies
  • Be on stable antihypertensive medication for pheochromocytoma-related hypertension for at least 30 days
  • Have at least one tumor site by CT or MR or iobenguane I 131 scan
  • Have an expected survival of at least 6 months
  • Subjects must agree to use an acceptable form of birth control (abstinence, IUD, oral contraception, barrier and spermicide or hormonal implant) during this study and for 6 months following Therapeutic Doses of Ultratrace Iobenguane I 131.
  • Male subjects must agree not to father a child during the period beginning immediately after administration of the first Therapeutic Dose of Ultratrace Iobenguane I 131 during the study and ending six months after administration of the last Therapeutic Dose of Ultratrace Iobenguane I 131.

Exclusion Criteria:

Subjects will be excluded if any of the following conditions are observed:

  • <50% of FDG (if data are available) positive lesions are MIBG avid
  • Pregnant or nursing females
  • Active CNS lesions by CT/MR scanning within 3 months of study entry
  • New York Heart Association class IV heart failure, symptomatic congestive heart failure [New York Heart Association class IV with another medical disorder], unstable angina pectoris, cardiac arrhythmia
  • Received any previous systemic radiotherapy resulting in marrow toxicity within 3 months of study entry or have active malignancy (other than pheochromocytoma/paraganglioma) requiring additional treatment during the active phase or follow up period of the Ultratrace® iobenguane I 131 trial.
  • Administered prior whole-body radiation therapy
  • Received external beam radiotherapy to > 25% of bone marrow
  • Administered prior chemotherapy within 30 days or have active malignancy (other than pheochromocytoma/ paraganglioma) requiring additional treatment during the active phase or follow up period of the Ultratrace iobenguane I 131 trial.
  • Karnofsky Performance Status is < 60
  • Platelets < 80,000/μL
  • Absolute neutrophil count (ANC) < 1,200/μL, Total bilirubin > 1.5 times the upper limit of normal, AST/SGOT or ALT/SGPT > 2.5 times the upper limit of normal
  • Diagnosed with AIDS or HIV-positive
  • Active chronic alcohol abuse, chronic liver disease or hepatitis
  • Renal dysfunction/impairment
  • Known allergy to iobenguane that has required medical intervention
  • Received a therapeutic investigational compound and/or medical device/prior chemotherapy within 30 days before admission into this study
  • Receiving a medication which inhibits tumor uptake of iobenguane I 131
  • Any medical condition or other circumstances (i.e., uncontrolled current illness including but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with the study requirements.
  • Any other condition, that in the opinion of the investigator, may compromise the safety or compliance of the subject or would preclude the subject from successful completion of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00874614

Contact: Jessica D Jensen, MPH 914-789-2843 jjensen@progenics.com

United States, California
University of California-San Francisco Not yet recruiting
San Francisco, California, United States, 94143
Contact: Samantha Wong    415-514-6759    samantha.wong@ucsf.edu   
Principal Investigator: Miguel Pampaloni, MD         
United States, Iowa
University of Iowa Recruiting
Iowa City, Iowa, United States, 52242
Contact: Debra Pfab    319-384-9164    debra-pfab@uiowa.edu   
Principal Investigator: Joseph Dillon, MD         
United States, Maryland
Johns Hopkins University Recruiting
Baltimore, Maryland, United States, 21287
Contact: Melin Vranesic    410-955-9547    mvranes1@jhmi.edu   
Principal Investigator: Lilja Solnes, MD         
United States, Missouri
Washington University School of Medicine, Alvin J. Siteman Cancer Center Recruiting
St. Louis, Missouri, United States, 63110
Contact: Jehan Ganachaud    314-747-9202    ganachaudj@wudosis.wustl.edu   
Principal Investigator: Jeffrey Olsen, MD         
United States, New York
Mount Sinai School of Medicine Withdrawn
New York, New York, United States, 10029
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Jennifer Korzekwinski    919-681-7362    jennifer.korzekwinski@dm.duke.edu   
Principal Investigator: Bennett Chin, MD         
United States, Pennsylvania
Hospital of the University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Tricia Tiu    215-746-8192    tricia.tiu@uphs.upenn.edu   
Principal Investigator: Daniel Pryma, MD         
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Madonna Pool    713-792-9851    MMPool@mdanderson.org   
Principal Investigator: Camillo Jimenez, MD         
Sponsors and Collaborators
Molecular Insight Pharmaceuticals, Inc.
Principal Investigator: Bennett Chin, MD Duke University
Principal Investigator: Daniel Pryma, MD University of Pennsylvania
Principal Investigator: Jeffrey Olsen, MD Mallinckrodt Institute of Radiology Washington University
Principal Investigator: Camillo Jimenez, MD MD Anderson Cancer
Principal Investigator: Joseph Dillon, MD University of Iowa
Principal Investigator: Lilja Solnes, MD Johns Hopkins University
Principal Investigator: Lale Kostakoglu, MD Icahn School of Medicine at Mount Sinai
Principal Investigator: Miguel Pampaloni, MD PhD University of California, San Francisco
  More Information

No publications provided

Responsible Party: Molecular Insight Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00874614     History of Changes
Other Study ID Numbers: MIP-IB12B
Study First Received: April 1, 2009
Last Updated: October 5, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Molecular Insight Pharmaceuticals, Inc.:
neuroendocrine tumors
Iobenguane I 131

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Antineoplastic Agents
Diagnostic Uses of Chemicals
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on December 01, 2015